D-(-)-Salicin
(Synonyms: 水杨苷; D-(?)-Salicin; Salicoside) 目录号 : GN10430
A non-selective COX inhibitor
Cas No.:138-52-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
|
Cell experiment: |
RAW264.7 mouse macrophage cell line is used in this study. RAW264.7 cells are mechanically scraped and plated at a density of 4×105 cells/mL onto 96-well plates in a 37°C, 5% CO2 incubator for 1 h. Then the cells are treated with 50 μL Salicin (D(-)-Salicin) of different concentrations (0 to 0.28 μM) for 1 h, followed by stimulation with 50 μL Lipopolysaccharide (LPS) (4 μg/mL). After 18 h, 10 μL CCK-8 is added to each well and continued to incubate for 4 h. Then, the optical density is measured at 450 nm on a microplate reader[2]. |
|
Animal experiment: |
Mice are randomly divided into five groups, each containing three mice: Control, Lipopolysaccharide (LPS) only, LPS+Salicin (D(-)-Salicin) group is injected intraperitoneally with Salicin 35 μM, LPS+Salicin group is injected intraperitoneally with Salicin 70 μM, LPS+Salicin group is injected intraperitoneally with Salicin 140 μM. After 1 h, 10 μg LPS dissolved in 50 μL PBS is instilled intranasally to induce lung injury. Control mice are given 50 μL PBS without LPS. After 12 h LPS treatment, bronchoalveolar lavage fluid (BALF) is collected 3 times through a tracheal cannula with autoclaved PBS. Then, the tissue sample is centrifuged at 3000 rpm, for 10 min at 4°C[2]. |
|
References: [1]. Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer. |
|
Salicin is a natural COX inhibitor.
Significant down regulation of PGE2, the enzymatic product of COX2, to 76% in lysate and 70% in supernatant is observed with Salicin 10 μM treatment in COLO cells when compare to the COLO control. This is accompanied with a minimal COX1 inhibition to 91% of the CCD control on the genetic level. Treatment with Salicin 1 μM decreases colon cancer cell proliferation rates from 144% to 113% at 24 hours and 187% to 130% at 48 hours, with 10 μM decreasing proliferation rates to108% at 24 hours and 119% at 48 hours[1]. The concentrations of TNF-α, IL-1β and IL-6 of LPS-induced cells pretreated with 0.07, 0.14 and 0.28 μM Salicin are significant reduced compare with LPS group[2].
Salicin (D(-)-Salicin) (35, 70, 140 μM) markedly inhibits the LPS-induced pathological changes. MPO activity in LPS-induced lung tissue is significantly increased compare with control group. However, Salicin (35, 70, 140 μM) markedly inhibits this change. Pretreatment with Salicin inhibits LPS-induced activation of JNK, ERK, p38/MAPK and p65 in a dose-dependent manner[2].
References:
[1]. Jun Yan He, et al. Salicin as a Multipurpose Therapeutic Approach for Colon Cancer.
[2]. Li Y, et al. D(-)-Salicin inhibits the LPS-induced inflammation in RAW264.7 cells and mouse models. Int Immunopharmacol. 2015 Jun;26(2):286-94.
| Cas No. | 138-52-3 | SDF | |
| 别名 | 水杨苷; D-(?)-Salicin; Salicoside | ||
| 化学名 | (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol | ||
| Canonical SMILES | C1=CC=C(C(=C1)CO)OC2C(C(C(C(O2)CO)O)O)O | ||
| 分子式 | C13H18O7 | 分子量 | 286.28 |
| 溶解度 | ≥ 14mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。